Objective—To measure antibody titers against
bovine coronavirus (BCV), determine frequency of
BCV in nasal swab specimens, and compare calves
treated for bovine respiratory tract disease (BRD)
between those given an intranasally administered
vaccine and control calves.
Design—Randomized clinical trial.
Animals—414 heifer calves.
Procedure—Intranasal BCV antigen concentration
and antibody titer against BCV were measured on
entry to a feedlot. Calves were randomly assigned to
receive 3.0 mL of a modified-live virus vaccine against
bovine enteric coronavirus and rotavirus or 3.0 mL of
saline (0.9% NaCl) solution. Calves were confined to
1 of 2 pens, depending on vaccination status, for a
minimum of 17 days of observation (range, 17 to 99).
Selection of calves for treatment of BRD and scoring
for severity of disease were done by veterinarians
unaware of treatment status.
Results—Intranasal BCV (125/407 [31%]) and serum
antibody titers ≥ 20 against BCV (246/396 [62%])
were identified in calves entering the feedlot.
Vaccination was associated with significant decrease
in risk of treatment for BRD; intranasal BCV on entry
to the feedlot was associated with increased risk of
treatment. Univariate analysis revealed that control
calves with intranasal BRD on entry to the feedlot and
those with antibody titer < 20 were significantly more
likely to be treated for BRD.
Conclusions and Clinical Relevance—These data
provide further evidence of an association between
BCV and respiratory tract disease in feedlot calves.
An intranasally administered vaccine appeared to
reduce risk of treatment for BRD. (J Am Vet Med